Press coverage about Axovant Sciences (NASDAQ:AXON) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Axovant Sciences earned a daily sentiment score of 0.04 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.4875076040547 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
A number of equities research analysts recently weighed in on AXON shares. BidaskClub cut Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 price objective for the company in a research note on Monday, October 9th. Robert W. Baird restated a “hold” rating and set a $6.00 price objective on shares of Axovant Sciences in a research note on Wednesday, November 1st. Oppenheimer restated a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 12th. Finally, Chardan Capital restated a “sell” rating and set a $3.00 price objective on shares of Axovant Sciences in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. Axovant Sciences presently has a consensus rating of “Hold” and an average target price of $13.61.
Axovant Sciences (NASDAQ:AXON) opened at $1.92 on Friday. Axovant Sciences has a 1 year low of $1.88 and a 1 year high of $27.98. The stock has a market capitalization of $195.60 and a PE ratio of -0.83. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.94 and a current ratio of 5.94.
Axovant Sciences (NASDAQ:AXON) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.09). equities analysts predict that Axovant Sciences will post -2.17 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/04/axovant-sciences-axon-earns-news-impact-score-of-0-04.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.